This Week in Cardiology — Jun 30, 2026

Welcome to This Week in Cardiology. This week we are covering eight notable papers spanning major updates in heart failure definitions, evolving antithrombotic and antiplatelet strategies, and precision cardio-oncology. Let us dive in.

We begin with a landmark consensus document published in the European Heart Journal that presents the Second Universal Definition of Heart Failure, compiled by a joint committee of the American Heart Association, the American College of Cardiology, the European Society of Cardiology, and the World Heart Federation [1]. This updated document aims to standardize terminology and resolve the subjectivity and ambiguity that have historically hindered clinical research, global disease surveillance, and prevention programs. A key clinical evolution in this second edition is the deliberate move away from rigid left ventricular ejection fraction cutoffs. Instead, the consensus groups heart failure into reduced, preserved, and improved ejection fraction categories to better capture the dynamic clinical realities and trajectories of our patients. It also reinforces the clinical utility of identifying Stage B, or pre-heart failure, to help clinicians identify and treat individuals at high risk before overt symptoms develop. The document proposes a universal classification of heart failure causes and highlights the dynamic trajectories of heart failure, including improvement, remission, and recovery. Crucially, it emphasizes how social determinants of health and geographic variations influence heart failure risk and patient outcomes globally. In a highly complementary area of clinical practice, a study in the European Heart Journal investigates therapeutic strategies for patients with heart failure with preserved ejection fraction and obesity, specifically focusing on the impact of incretin therapy on weight loss, exercise hemodynamics, and overall patient health status [4]. As we strive to implement these standardized definitions and therapies, a review in Nature Reviews Cardiology calls our attention to the critical need for inclusive cardiovascular care for sexual and gender minority populations [8]. The authors highlight how addressing the unique risk factors and healthcare barriers faced by these underserved populations is essential to achieving equitable cardiovascular care, aligning directly with the new universal definition's call to address social determinants of health.

Next, we turn to significant therapeutic and diagnostic developments in the management of transthyretin amyloid cardiomyopathy, or ATTR cardiomyopathy. Writing in Nature Medicine, researchers published the long-term follow-up results of the NI006-101 trial evaluating cliramitug, a monoclonal antibody that directly targets and depletes misfolded transthyretin from cardiac tissue [5]. While traditional therapies like tafamidis work by stabilizing the transthyretin protein, cliramitug represents a novel approach to actively clearing existing amyloid deposits. In this second open-label extension study, twenty-three male participants, twenty of whom were on background tafamidis therapy, received a median of ten additional infusions, extending the median follow-up to twenty-nine point three months and maximum exposure to twenty-four infusions. Thirteen participants who were initially treated with ten milligrams per kilogram or less were up-titrated to a higher dose of thirty milligrams per kilogram. The treatment was exceptionally well-tolerated, with a ninety-eight percent adherence rate and absolutely no treatment-related serious adverse events or therapy discontinuations. Most importantly, continued treatment and dose up-titration led to progressive reductions in cardiac extracellular volume on magnetic resonance imaging and decreased tracer uptake on bisphosphonate scintigraphy, demonstrating a time- and dose-dependent depletion of cardiac amyloid burden. Patients also showed significant improvements in cardiac biomarkers, including N-terminal pro-B-type natriuretic peptide and troponin T, along with favorable changes in left ventricular relaxation, filling pressures, and wall thickness. These structural and functional improvements translated into meaningful quality-of-life benefits, as evidenced by rising Kansas City Cardiomyopathy Questionnaire scores. On the diagnostic front, a study in the European Journal of Heart Failure provides valuable insight into risk stratification for patients with suspected ATTR cardiomyopathy [6]. The investigators found that high serum transthyretin concentrations identify a low likelihood of advanced myocardial amyloid burden. In clinical practice, this simple and accessible laboratory marker could help clinicians identify patients who are unlikely to have advanced cardiac amyloid deposition, potentially streamlining the diagnostic workup and helping to guide the appropriate use of advanced imaging and specialized therapies.

In the field of cardio-oncology, a prospective longitudinal study published in the European Heart Journal utilizes high-throughput proteomic and metabolomic profiling to shed light on the biological pathways of chemotherapy-induced cardiotoxicity [7]. The researchers followed a cohort of five hundred and forty-seven breast cancer patients, with a median age of fifty years, who were undergoing treatment with anthracyclines, trastuzumab, or both. Using the Olink Explore platform and liquid chromatography-mass spectrometry, they analyzed repeated measures of circulating proteins and metabolites to identify contemporaneous and lagged associations with quantitative echocardiographic measures of cardiac structure and function. They identified two hundred and three unique proteins and sixteen unique metabolites that were significantly associated with left ventricular mass, left atrial volume index, left ventricular ejection fraction, longitudinal and circumferential strain, and ventricular-arterial coupling. Notably, the protein cathepsin C was significantly associated with left ventricular ejection fraction, longitudinal strain, left atrial volume index, and a lower risk of incident cardiac dysfunction, which was defined as an ejection fraction decline of ten percent or more to a level below fifty percent. Cathepsin C was associated with a hazard ratio of zero point six one for incident dysfunction, indicating a significant protective association or marker of myocardial resilience. The proteins associated with cardiac function were enriched in pathways involving protein deubiquitination, macromolecule catabolic processes, and global metabolic pathways. Furthermore, specific metabolites, including n-acetylglutamine, aspartic acid, acetylasparagine, alanyl-alanine, and prolyl-glycine, demonstrated highly significant associations with left ventricular ejection fraction and longitudinal strain. These findings provide profound translational insights into the mechanisms of cardiac remodeling during cardiotoxic cancer therapies, presenting novel candidates for biomarker development to help clinicians identify at-risk patients before irreversible structural damage occurs.

Finally, we examine two comprehensive scientific statements from the American College of Cardiology, published in the Journal of the American College of Cardiology, which standardize and optimize antithrombotic therapies. The first statement provides a detailed overview of antiplatelet therapy in the management of atherosclerotic cardiovascular disease [2]. The authors emphasize that recommendations have evolved significantly over the past decade. Most notably, recent data do not support a benefit for the routine use of aspirin in the primary prevention of cardiovascular disease in unselected populations, recommending that its use be strictly reserved for individuals at the absolute highest ischemic risk. For patients with established atherosclerotic disease, particularly those who have experienced an acute coronary syndrome or undergone coronary intervention with drug-eluting stents, the statement reviews the shifting evidence for the optimal selection and duration of dual antiplatelet therapy. It highlights that the perpetual challenge of balancing ischemic prevention against bleeding risk requires highly individualized, patient-centered treatment decisions and careful long-term monitoring. The second scientific statement addresses the clinical implementation of direct oral anticoagulants, or DOACs, for the primary and secondary prevention of thrombotic events [3]. Although DOACs have become the preferred agents for most patients with atrial fibrillation and venous thromboembolism due to their safety and predictable pharmacokinetics, the statement highlights that they remain underutilized and are frequently inappropriately dosed. This is especially true for patients at high thrombotic risk and populations historically underrepresented in clinical trials. The statement provides evidence-based guidance to help clinicians navigate DOAC therapy in highly complex patient populations, including those with chronic kidney disease, liver dysfunction, active cancer, obesity, frailty, prior bleeding, and valvular heart disease. It also addresses practical clinical challenges such as drug selection, dosing strategies, periprocedural anticoagulation, and antithrombotic management following stroke, left atrial appendage closure, and catheter ablation.

If you only have time for one paper this week, make it the Second Universal Definition of Heart Failure [1]. This landmark consensus document from major global cardiac societies is highly practice-changing, as it abandons rigid ejection fraction boundaries in favor of dynamic clinical phenotypes and formally integrates social determinants of health into our global approach to heart failure prevention and care.

Here are the key takeaways from this week in Cardiology. First, the classification of heart failure has been updated to emphasize dynamic categories—reduced, preserved, and improved ejection fraction—while highlighting the importance of early detection in Stage B pre-heart failure and the impact of social and geographic disparities [1]. Second, for patients with ATTR cardiomyopathy, long-term treatment with the amyloid-depleting monoclonal antibody cliramitug is safe and leads to dose-dependent reductions in cardiac amyloid burden and improvements in cardiac function [5], while high serum transthyretin levels can help identify patients with a low likelihood of advanced myocardial amyloid burden [6]. Third, circulating levels of cathepsin C and specific amino acid metabolites serve as promising biomarkers for predicting and monitoring cardiotoxicity in breast cancer patients receiving anthracyclines or trastuzumab [7]. Fourth, routine aspirin is not recommended for primary cardiovascular prevention in unselected patients, and dual antiplatelet therapy must be tailored individually to balance bleeding and ischemic risks [2]. Finally, direct oral anticoagulants remain underutilized and often incorrectly dosed; clinicians should utilize the latest consensus guidance to optimize DOAC therapy in complex and frail patient populations [3].

That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.